• Home
  • About IMWG
    • Mission
    • History
  • Publications
  • Summaries
  • Events
    • Annual Summit
    • Robert A. Kyle Lifetime Achievement Award
  • Multimedia
    • Conference Series
    • Photo Gallery
  • Home
  • About IMWG
    • Mission
    • History
  • Publications
  • Summaries
  • Events
    • Annual Summit
    • Robert A. Kyle Lifetime Achievement Award
  • Multimedia
    • Conference Series
      • ASH 2018 – San Diego
      • Stockholm 2018
      • ASH 2017 – Atlanta, GA
      • Madrid 2017
      • ASH 2016
      • Copenhagen 2016
      • ASH 2015
      • Vienna 2015
      • ASH 2014
      • Milan 2014
    • Photo Gallery

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

By imwgimf On July 28, 2016 · Add Comment · In Diagnosis, Staging & Monitoring, IMWG Publications
The updated criteria for the diagnosis of myeloma represent a paradigm shift in the approach to myeloma and have considerable impact on the management of the disease. For decades the diagnosis of multiple myeloma required the presence of end-organ damage known as the CRAB criteria, including increased calcium level, renal dysfunction, anemia, and destructive bone lesions. The updated criteria allow for treatment of patients who are at such high risk of progression to symptomatic disease that it is clear they would benefit from therapy and also potentially live longer if they were treated before serious organ damage occurred. The revised IMWG criteria allow, in addition to the classic CRAB features, […]
Read More »
 
  • Popular
  • Recent
  • Comments
  • Tags
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe updated criteria for the diagnosis of myeloma represent a [...]
  • International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma
  • IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
  • Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupWhole Body Low Dose CT (WBLDCT) has important advantages as [...]
  • Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American CountriesLatin American countries (LATAMC) represent a large fraction of patients [...]
  • Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupFor decades conventional skeletal survey (CSS) has been the standard [...]
  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG studyIntroduction of new myeloma therapies offers new options for patients [...]
ASCT bone disease bortezomib classification computed tomography consensus cytogenetics diagnosis DVT genetic guidelines IMWG International myeloma working group International Staging System ISS lenalidomide magnetic resonance imaging molecular multiple myeloma myeloma patients prognosis response criteria stem cell survival thalidomide therapy thrombosis transplantation treatment
  • Categories

    • Diagnosis, Staging & Monitoring
    • Guidelines
    • IMWG Publications
    • Maintenance
    • Relapse
    • Supportive Care
    • Transplant
    • Treatment Options
  • Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
    To find out more, including how to control cookies, see here: Cookie Policy
  • Search

 
© 2019 IMWG